You just read:

FDA Grants Priority Review for Daiichi Sankyo's New Drug Application for CSF1R Inhibitor Pexidartinib for Treatment of Patients with TGCT, a Rare, Debilitating Tumor

News provided by

Daiichi Sankyo Company, Limited

Feb 05, 2019, 08:00 ET